Literature DB >> 31737332

Driving the discussion about the greater propensity for doing better with neoadjuvant chemotherapy for non-small cell lung cancer.

Abigail K Zamora1, Anthony W Kim1.   

Abstract

Entities:  

Year:  2019        PMID： 31737332      PMCID： PMC6837990          DOI： 10.21037/jtd.2019.09.44

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall.

Authors:  Sarah J Gao; Christopher D Corso; Justin D Blasberg; Frank C Detterbeck; Daniel J Boffa; Roy H Decker; Anthony W Kim
Journal:  Clin Lung Cancer       Date:  2016-10-17       Impact factor: 4.785

Review 2.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Klaus F Rabe
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

3.  Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

Authors:  Giorgio V Scagliotti; Ugo Pastorino; Johan F Vansteenkiste; Lorenzo Spaggiari; Francesco Facciolo; Tadeusz M Orlowski; Luigi Maiorino; Martin Hetzel; Monika Leschinger; Carla Visseren-Grul; Valter Torri
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

4.  Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.

Authors:  Katherine M W Pisters; Eric Vallières; John J Crowley; Wilbur A Franklin; Paul A Bunn; Robert J Ginsberg; Joe B Putnam; Kari Chansky; David Gandara
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

5.  Now or later: evaluating the importance of chemotherapy timing in resectable stage III (N2) lung cancer in the National Cancer Database.

Authors:  Daniel J Boffa; Jacquelyn G Hancock; Xiaopan Yao; Sarah Goldberg; Joshua E Rosen; Anthony W Kim; Amy Moreno; Frank C Detterbeck
Journal:  Ann Thorac Surg       Date:  2014-11-20       Impact factor: 4.330

Review 6.  First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

Authors:  Christoph Jakob Ackermann; Martin Reck; Luis Paz-Ares; Fabrice Barlesi; Raffaele Califano
Journal:  Lung Cancer       Date:  2019-06-19       Impact factor: 5.705

7.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Authors:  Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

8.  Treating locally advanced disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base.

Authors:  Amy C Moreno; Daniel Morgensztern; Daniel J Boffa; Roy H Decker; James B Yu; Frank C Detterbeck; Zuoheng Wang; Michal G Rose; Anthony W Kim
Journal:  Ann Thorac Surg       Date:  2014-02-26       Impact factor: 4.330

Review 9.  Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

Authors:  Eric Lim; Grace Harris; Amit Patel; Iki Adachi; Lyn Edmonds; Fujian Song
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

10.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.